A 58-year-old postmenopausal woman from rural India presents with abnormal vaginal bleeding for 3 months. On examination, she is obese (BMI 34 kg/m²) and has a blood pressure of 150/95 mmHg. Endometrial biopsy reveals adenocarcinoma. What is the most common risk factor for endometrial carcinoma in this patient?

## Risk Factors for Endometrial Carcinoma **Key Point:** Unopposed estrogen exposure is the most common and most important risk factor for endometrial carcinoma, accounting for the majority of Type I (endometrioid) cancers. ### Classification of Endometrial Cancer by Risk Factor ```mermaid flowchart TD A[Endometrial Carcinoma Risk Factors]:::outcome --> B{Estrogen-Dependent?}:::decision B -->|Yes - Type I| C[Unopposed Estrogen]:::action B -->|No - Type II| D[Non-Estrogen-Dependent]:::action C --> E[Obesity, PCOS, Diabetes, HRT] C --> F[Endometrioid adenocarcinoma] D --> G[Age, Atrophy, Serous/Clear cell] D --> H[Worse prognosis] ``` ### Unopposed Estrogen: Mechanism and Sources **High-Yield:** Unopposed estrogen leads to: 1. Chronic endometrial proliferation 2. Increased mitotic activity 3. Accumulation of genetic mutations 4. Evolution from simple hyperplasia → complex hyperplasia → atypical hyperplasia → carcinoma **Sources of unopposed estrogen:** - **Obesity:** Peripheral aromatization of androgens to estrone in adipose tissue (most common source in postmenopausal women) - **Polycystic ovary syndrome (PCOS):** Anovulation → unopposed estrogen - **Estrogen-only hormone replacement therapy (HRT):** Without progestin - **Granulosa cell tumors / other estrogen-secreting ovarian tumors** ### Clinical Correlation in This Case **Clinical Pearl:** This patient has multiple Type I endometrial cancer risk factors: - **Obesity (BMI 34):** Primary source of unopposed estrogen via peripheral aromatization - **Postmenopausal age (58 years):** Loss of ovarian estrogen suppression - **Hypertension (150/95):** Associated metabolic syndrome - **Abnormal vaginal bleeding:** Early presentation (often Stage I–II) The combination of obesity, postmenopausal status, and early-stage adenocarcinoma is classic for Type I (estrogen-dependent) endometrial cancer. ### Comparison of Risk Factors | Risk Factor | Type of Cancer | Frequency | Mechanism | | --- | --- | --- | --- | | Unopposed estrogen | Type I (Endometrioid) | **Most common** | Chronic proliferation | | Lynch syndrome | Type I or II | Rare (~2–3%) | Mismatch repair defect | | Tamoxifen | Type I (Endometrioid) | ~2–3% of breast cancer patients | Partial estrogen agonist | | Pelvic radiation | Type II (Serous/Clear cell) | Rare | Direct mutagenesis | **Warning:** Do not confuse tamoxifen (which increases risk via estrogenic effects) with aromatase inhibitors (which reduce endometrial cancer risk by lowering estrogen). ### Why Other Options Are Less Common - **Lynch syndrome:** Accounts for only 2–3% of endometrial cancers; autosomal dominant; associated with colorectal cancer; presents at younger age (mean 48–50 years) - **Tamoxifen:** Increases risk in ~2–3% of breast cancer patients; acts as partial estrogen agonist in endometrium; increases risk of both hyperplasia and carcinoma - **Pelvic radiation:** Rare cause; typically causes Type II (serous/clear cell) cancers; latency period of 10–20+ years; usually presents at advanced stage **Mnemonic:** **PCOS-HRT-OB** for unopposed estrogen sources: - **P**olycystic ovary syndrome - **C**ontinuous estrogen (HRT without progestin) - **O**besity - **S**ecretory tumors (granulosa cell) - **H**ormone replacement therapy - **R**are ovarian tumors - **O**besity (repeated for emphasis) - **B**ody weight (adipose tissue aromatization)